This is the primary focus for now and the future for Lilly
MAMPs comprise Lipopolysaccharides (LPS), peptidoglycan, lipid A, bacterial DNA/ RNA, flagella, and -glucans in the fungal cell wall [48, 49]
Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial
Notably, engineered EVs show promise as biocompatible drug carriers to overcome therapeutic resistance [53,54] , with strategies like peptide-functionalized bacterial EVs demonstrating targeted miRNA delivery efficacy in bone diseases [58] , reinforcing the potential of engineered EVs to overcome therapeutic resistance
GLP-1RAs effects are relevant to MS, with potential to modulate inflammation, promote remyelination, and to stabilize the BBB